Fibryga (R) is now approved in the U.S. for fibrinogen supplementation in both congenital and acquired fibrinogen deficiency, and is available in 1-gram and 2-gram kits, each with the nextaro (R) ...

Add Yahoo as a preferred source to see more of our stories on Google. The new kit contains 100ml Water for Infusion and includes the nextaro reconstitution device. Credit: Octapharma / PRNewswire.

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for ...

Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate 14.02.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS ...

DALLAS--(BUSINESS WIRE)--Bloodbuy, a healthcare software and services company focused on developing cloud-based technologies that transform how biological products are managed and disseminated, today ...

What Is Fesilty, and Why Does It Matter? Fesilty (fibrinogen, human-chmt) is a newly approved treatment for sudden bleeding episodes in both children and adults with a rare condition called congenital ...

PARAMUS, N.J, Aug. 1, 2024 /PRNewswire/ -- Octapharma USA, Inc. has announced the expanded approval of fibryga ®, Fibrinogen (Human) Lyophilized Powder for Reconstitution, for fibrinogen replacement ...

Biotest AG: Biotest achieves important milestone in Phase III study in acquired fibrinogen deficiency 10.06.2022 / 07:00 The issuer is solely responsible for the content of this announcement. PRESS ...

PARAMUS, N.J., Jan. 7, 2026 /PRNewswire/ -- Octapharma USA, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new 2-gram presentation of Fibryga ®, Fibrinogen (Human ...

Fibryga is a human plasma-derived fibrinogen concentrate authorised for AFD in the US.